Cargando…
Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life
Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as “the administration of many drugs at the same time or the administration of an excessive number of drugs”. The primary goal of this study was to...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415215/ https://www.ncbi.nlm.nih.gov/pubmed/37576859 http://dx.doi.org/10.1016/j.jsps.2023.06.001 |
_version_ | 1785087478226485248 |
---|---|
author | Farooq, Juveriya Sana, M.M. Chetana, P.M. Almuqbil, Mansour Prabhakar Bhat, Nagapati Sultana, Rokeya Khaiser, UmaimaFarheen Mohammed Basheeruddin Asdaq, Syed Almalki, Mutlaq Eidhah M. Mohammed sawadi Khormi, Amro Ahmad Albraiki, Salem Almadani, Moneer E. |
author_facet | Farooq, Juveriya Sana, M.M. Chetana, P.M. Almuqbil, Mansour Prabhakar Bhat, Nagapati Sultana, Rokeya Khaiser, UmaimaFarheen Mohammed Basheeruddin Asdaq, Syed Almalki, Mutlaq Eidhah M. Mohammed sawadi Khormi, Amro Ahmad Albraiki, Salem Almadani, Moneer E. |
author_sort | Farooq, Juveriya |
collection | PubMed |
description | Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as “the administration of many drugs at the same time or the administration of an excessive number of drugs”. The primary goal of this study was to evaluate polypharmacy in patients with chronic liver disease and to identify potential drug-drug interactions associated with it. A cross-sectional study was conducted at a tertiary care hospital in Mangalore, Karnataka, for six months, from November 2020 to April 2021. The study involved 118 patients with chronic liver disease from various age groups. Data was gathered by analyzing patients' medical records kept on the ward and interviewing them individually. In admission and discharge prescriptions, polypharmacy was examined. Online interaction checkers from Drugs.com and Medscape were used to interpret potential drug-drug interactions. The SF-36 and Chronic Liver Disease Questionnaire were used to measure the quality of life. The data obtained were analyzed statistically to determine the significant correlation. The number of prescribed drugs was significantly correlated (P = 0.018) with the severity of liver disease in Child-Pugh categories B and C. Additionally, moderate polypharmacy reduced quality of life (P < 0.05), and the physical health category was significantly associated with disease severity (P < 0.05). Drug-drug interactions were found in 108 out of the 118 examined prescriptions, totaling 586 interactions in the admission list and 405 interactions in the discharge list. If the potentially serious main drug interaction identified in this study is not well monitored, it could lead to a serious, potentially fatal health condition. Despite being advised, safety is not always guaranteed by liver enzyme monitoring. Therefore, healthcare providers must take additional precautions to avoid inappropriate prescribing, minimize side effects, and ensure drug safety. |
format | Online Article Text |
id | pubmed-10415215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104152152023-08-12 Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life Farooq, Juveriya Sana, M.M. Chetana, P.M. Almuqbil, Mansour Prabhakar Bhat, Nagapati Sultana, Rokeya Khaiser, UmaimaFarheen Mohammed Basheeruddin Asdaq, Syed Almalki, Mutlaq Eidhah M. Mohammed sawadi Khormi, Amro Ahmad Albraiki, Salem Almadani, Moneer E. Saudi Pharm J Original Article Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as “the administration of many drugs at the same time or the administration of an excessive number of drugs”. The primary goal of this study was to evaluate polypharmacy in patients with chronic liver disease and to identify potential drug-drug interactions associated with it. A cross-sectional study was conducted at a tertiary care hospital in Mangalore, Karnataka, for six months, from November 2020 to April 2021. The study involved 118 patients with chronic liver disease from various age groups. Data was gathered by analyzing patients' medical records kept on the ward and interviewing them individually. In admission and discharge prescriptions, polypharmacy was examined. Online interaction checkers from Drugs.com and Medscape were used to interpret potential drug-drug interactions. The SF-36 and Chronic Liver Disease Questionnaire were used to measure the quality of life. The data obtained were analyzed statistically to determine the significant correlation. The number of prescribed drugs was significantly correlated (P = 0.018) with the severity of liver disease in Child-Pugh categories B and C. Additionally, moderate polypharmacy reduced quality of life (P < 0.05), and the physical health category was significantly associated with disease severity (P < 0.05). Drug-drug interactions were found in 108 out of the 118 examined prescriptions, totaling 586 interactions in the admission list and 405 interactions in the discharge list. If the potentially serious main drug interaction identified in this study is not well monitored, it could lead to a serious, potentially fatal health condition. Despite being advised, safety is not always guaranteed by liver enzyme monitoring. Therefore, healthcare providers must take additional precautions to avoid inappropriate prescribing, minimize side effects, and ensure drug safety. Elsevier 2023-08 2023-06-09 /pmc/articles/PMC10415215/ /pubmed/37576859 http://dx.doi.org/10.1016/j.jsps.2023.06.001 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Farooq, Juveriya Sana, M.M. Chetana, P.M. Almuqbil, Mansour Prabhakar Bhat, Nagapati Sultana, Rokeya Khaiser, UmaimaFarheen Mohammed Basheeruddin Asdaq, Syed Almalki, Mutlaq Eidhah M. Mohammed sawadi Khormi, Amro Ahmad Albraiki, Salem Almadani, Moneer E. Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life |
title | Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life |
title_full | Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life |
title_fullStr | Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life |
title_full_unstemmed | Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life |
title_short | Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life |
title_sort | polypharmacy in chronic liver disease patients: implications for disease severity, drug-drug interaction, and quality of life |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415215/ https://www.ncbi.nlm.nih.gov/pubmed/37576859 http://dx.doi.org/10.1016/j.jsps.2023.06.001 |
work_keys_str_mv | AT farooqjuveriya polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT sanamm polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT chetanapm polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT almuqbilmansour polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT prabhakarbhatnagapati polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT sultanarokeya polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT khaiserumaimafarheen polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT mohammedbasheeruddinasdaqsyed polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT almalkimutlaqeidhahm polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT mohammedsawadikhormiamro polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT ahmadalbraikisalem polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife AT almadanimoneere polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife |